Authors
Latest:
Dr. Wierda on the Fixed-Duration Cohort Results of CAPTIVATE Trial in CLLWilliam G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.
Latest:
Dr Wierda on the Genomic Evolution of Pirtobrutinib in Pretreated CLLWilliam G. Wierda, MD, PhD, discusses the genomic evolution of pirtobrutinib in pretreated chronic lymphocytic leukemia.
Latest:
Rapid Readouts: Phase 1 Cohort of TRANSCEND-CLL-004 StudyWilliam G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.
Latest:
Dr. Gradishar on Integrating Novel Options Into the HER2+ Breast Cancer Treatment AlgorithmWilliam Gradishar, MD, discusses factors to consider when determining the optimal treatment of patients with HER2-positive breast cancer.
Latest:
Future Directions in Care for HER2+ Breast CancerBefore closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.
Latest:
New Strategies Shift Landscape in HR+ Metastatic Breast CancerThere has been much progress in the treatment of estrogen receptor-positive metastatic breast cancer over the past 40 years, and novel therapies are further expanding therapeutic options.
Latest:
Therapeutic Advances in Prophylaxis Against CINAn overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.
Latest:
Dr. Kelly on the Next Steps With Radium-223 and Niraparib in mCRPCWilliam K. Kelly, DO, discusses the next steps with the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.
Latest:
Dr. Oh on Challenges With Developing Novel Targeted Agents in Prostate CancerWilliam K. Oh, MD, discusses challenges with developing novel targeted agents in prostate cancer.
Latest:
Dr. Kelly on Radium-223 Dichloride and Niraparib in Patients With mCRPCWilliam K. Kelly, DO, discusses results from a phase 1b dose-finding study (NCT03076203) evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Dahut on the Future of Genetic Screening in Prostate CancerWilliam L. Dahut, MD, discusses the future of genetic screening in prostate cancer.
Latest:
Dr. Dahut on the Future of Genetic Screening in Prostate CancerWilliam L. Dahut, MD, discusses the future of genetic screening in prostate cancer.
Latest:
Dr. Grady on Gene Profiling of CTCs in Pancreatic CancerWilliam M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from an ongoing prospective study looking at gene expression profiling of circulating tumor cells in patients with unresectable pancreatic cancer.
Latest:
Dr. Oh on the Management of Hormone-Sensitive Prostate CancerWilliam Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the management of patients with hormone-sensitive prostate cancer.
Latest:
Dr. Tew Evaluates Avastin Treatment in Ovarian CancerWilliam P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates bevacizumab (Avastin) as a treatment for women with ovarian cancer
Latest:
Direct Targeting of RET Aberrations Moves Closer to the ClinicOver the past 30 years, from the discovery of a fusion rearrangement to the recent promise of LOXO-292, RET targeting has gone from distant concept toward clinical reality.
Latest:
Dr. Berry on Novel Imaging Techniques for Prostate CancerWilliam R. Berry, MD, medical oncologist, Duke University, discusses novel imaging techniques for patients with prostate cancer.
Latest:
Dr. Gwin on Potential Areas of Investigation With Alpha-TEA/Trastuzumab in Breast CancerWilliam R. Gwin III, MD, discusses potential areas of investigation with the combination of alpha-tocopheryloxyacetic acid (alpha-TEA) and trastuzumab (Herceptin) in breast cancer.
Latest:
Dr. Jarnagin on Surgical Protocols for CRC That Have Spread Beyond the LiverWilliam R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the surgical barriers in treating patients with colorectal cancer that has metastasized outside of the liver.
Latest:
Dr. Jarnagin on the Improvements in Surgery for Patients With mCRCWilliam R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer.
Latest:
Palliative Care Issues in Gynecologic CancerPalliative care should address the unique symptom profile of gynecologic cancer and be tailored to individual socioeconomic environments.
Latest:
Dr. DeRosa Discusses Nab-Paclitacel in Lung CancerWilliam T. DeRosa, DO, from Carol G. Simon Cancer Center at Morristown Memorial Hospital, discusses subset analyses from the phase III CA031 trial that examined nab-paclitaxel in non-small cell lung cancer.
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment RecommendationsResearchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
Latest:
Individualized Approach to Treatment for the Elderly Ovarian Cancer PatientStuart Lichtman, MD, and William Tew, MD, from Memorial Sloan-Kettering Cancer Center, discuss personalizing treatment for elderly patients with ovarian cancer.
